Survey of urologists over the management of benign prostatic hyperplasia in India
Background: The benign enlargement of the prostate gland is known as benign prostatic hyperplasia (BPH). It refers to stromal and glandular epithelial hyperplasia that develops in the region of the prostate that surrounds the urethra known as the periurethral transition zone. Aims and Objectives:...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Manipal College of Medical Sciences, Pokhara
2022-11-01
|
| Series: | Asian Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://www.nepjol.info/index.php/AJMS/article/view/48611 |
| _version_ | 1811333586118246400 |
|---|---|
| author | Meghna Pandey Shweta Sharma Dinesh Kumar Yadav Yogendra Kumar Gupta Komal |
| author_facet | Meghna Pandey Shweta Sharma Dinesh Kumar Yadav Yogendra Kumar Gupta Komal |
| author_sort | Meghna Pandey |
| collection | DOAJ |
| description | Background: The benign enlargement of the prostate gland is known as benign prostatic hyperplasia (BPH). It refers to stromal and glandular epithelial hyperplasia that develops in the region of the prostate that surrounds the urethra known as the periurethral transition zone.
Aims and Objectives: The aim of the study was to perform a survey of urologists over the management of BPH in India.
Materials and Methods: A survey questionnaire was e-mailed to a random sample of 57 urologists of India through surveymonkey.com. The enrolled questionnaires were statistically analyzed. Of the 57 questionnaires sent, nine were returned, and 48 of those were included in the final analysis (response rate of 84.21%).
Results: Majority of urologists’ opinion is that USG-KUB with uroflowmetry is the most reliable investigation for diagnosis of BPH. Tamsulosin (tamsulosin 0.4 mg) was the most preferred α-1 selective blocker drug in BPH patients across all the age groups, whereas silodosin was the most preferred α-1 selective blocker drug in cardiac patients having BPH. The preferred 5-alpha reductase inhibiting drug and dose was recorded as dutasteride 0.5 mg/day. Solifenacin is the preferred anti-cholinergic drug for urinary urgency and incontinence. The IPSS score of the patient improved usually within 1–6 weeks of treatment with alpha blockers/5-alpha reductase inhibitor. As per Indian urologists, the drug therapy with alpha blockers gave the fastest symptomatic improvement in BPH patients.
Conclusion: In our conclusion, there is no uniformity in the treatment of acute urinary retention; however, the overall care must be individualized for the patient. Lack of understanding of the population’s history of BPH hinders advancement in appropriate care. |
| first_indexed | 2024-04-13T16:55:12Z |
| format | Article |
| id | doaj.art-87455a1c97bb441c83c775d266612ca7 |
| institution | Directory Open Access Journal |
| issn | 2467-9100 2091-0576 |
| language | English |
| last_indexed | 2024-04-13T16:55:12Z |
| publishDate | 2022-11-01 |
| publisher | Manipal College of Medical Sciences, Pokhara |
| record_format | Article |
| series | Asian Journal of Medical Sciences |
| spelling | doaj.art-87455a1c97bb441c83c775d266612ca72022-12-22T02:38:50ZengManipal College of Medical Sciences, PokharaAsian Journal of Medical Sciences2467-91002091-05762022-11-01131193100https://doi.org/10.3126/ajms.v13i11.48611Survey of urologists over the management of benign prostatic hyperplasia in IndiaMeghna Pandey 0Shweta Sharma 1https://orcid.org/0000-0003-4032-0634Dinesh Kumar Yadav 2https://orcid.org/0000-0001-7999-5204Yogendra Kumar Gupta 3Komal 4https://orcid.org/0000-0003-4515-2553Professor, Department of Pharmacology, World College of Medical Sciences and Research, Pandit Bhagwat Dayal University of Health Sciences, Jhajjar, Haryana, IndiaAssistant Professor, Department of Pharmacology, Al-Falah School of Medical Sciences and Research, Al-Falah University, Faridabad, Haryana Assistant Professor, Department of Pharmacology, Al-Falah School of Medical Sciences and Research, Al-Falah University, Faridabad, Haryana President, All India Institute of Medical Sciences, Bhopal, Madhya PradeshMedical Officer, Haryana Civil Medical Services, Haryana, India Background: The benign enlargement of the prostate gland is known as benign prostatic hyperplasia (BPH). It refers to stromal and glandular epithelial hyperplasia that develops in the region of the prostate that surrounds the urethra known as the periurethral transition zone. Aims and Objectives: The aim of the study was to perform a survey of urologists over the management of BPH in India. Materials and Methods: A survey questionnaire was e-mailed to a random sample of 57 urologists of India through surveymonkey.com. The enrolled questionnaires were statistically analyzed. Of the 57 questionnaires sent, nine were returned, and 48 of those were included in the final analysis (response rate of 84.21%). Results: Majority of urologists’ opinion is that USG-KUB with uroflowmetry is the most reliable investigation for diagnosis of BPH. Tamsulosin (tamsulosin 0.4 mg) was the most preferred α-1 selective blocker drug in BPH patients across all the age groups, whereas silodosin was the most preferred α-1 selective blocker drug in cardiac patients having BPH. The preferred 5-alpha reductase inhibiting drug and dose was recorded as dutasteride 0.5 mg/day. Solifenacin is the preferred anti-cholinergic drug for urinary urgency and incontinence. The IPSS score of the patient improved usually within 1–6 weeks of treatment with alpha blockers/5-alpha reductase inhibitor. As per Indian urologists, the drug therapy with alpha blockers gave the fastest symptomatic improvement in BPH patients. Conclusion: In our conclusion, there is no uniformity in the treatment of acute urinary retention; however, the overall care must be individualized for the patient. Lack of understanding of the population’s history of BPH hinders advancement in appropriate care.https://www.nepjol.info/index.php/AJMS/article/view/48611benign prostatic hyperplasia; questionnaire; urologists |
| spellingShingle | Meghna Pandey Shweta Sharma Dinesh Kumar Yadav Yogendra Kumar Gupta Komal Survey of urologists over the management of benign prostatic hyperplasia in India Asian Journal of Medical Sciences benign prostatic hyperplasia; questionnaire; urologists |
| title | Survey of urologists over the management of benign prostatic hyperplasia in India |
| title_full | Survey of urologists over the management of benign prostatic hyperplasia in India |
| title_fullStr | Survey of urologists over the management of benign prostatic hyperplasia in India |
| title_full_unstemmed | Survey of urologists over the management of benign prostatic hyperplasia in India |
| title_short | Survey of urologists over the management of benign prostatic hyperplasia in India |
| title_sort | survey of urologists over the management of benign prostatic hyperplasia in india |
| topic | benign prostatic hyperplasia; questionnaire; urologists |
| url | https://www.nepjol.info/index.php/AJMS/article/view/48611 |
| work_keys_str_mv | AT meghnapandey surveyofurologistsoverthemanagementofbenignprostatichyperplasiainindia AT shwetasharma surveyofurologistsoverthemanagementofbenignprostatichyperplasiainindia AT dineshkumaryadav surveyofurologistsoverthemanagementofbenignprostatichyperplasiainindia AT yogendrakumargupta surveyofurologistsoverthemanagementofbenignprostatichyperplasiainindia AT komal surveyofurologistsoverthemanagementofbenignprostatichyperplasiainindia |